The Oklahoma Medical Research Foundation has received a $3 million grant to study Parkinson's disease, potentially leading to ...

Parkinson’s patients and their caregivers attended the first “Parkinson’s Today:  An Educational Symposium” in Palm Desert on Saturday.  PRO or Parkinson’s Resource Organization teamed up with The ...

Sep. 24, 2024 — Parkinson's disease, a debilitating nervous system disorder, is treated with medications that sometimes cause impaired decision-making and poor ... Some Diabetes Drugs Tied to ...

Samsung is recognizing Española Valley High School for its student’s efforts to help people dealing with Parkinson’s Disease. Students, in coordination with ...

The U.S. Food and Drug Administration (FDA) has approved Onapgo (apomorphine hydrochloride) injection, the first and only ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's disease have taken an hit.A new study ...

The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...